|
|
xvii | |
Biographies |
|
xxiii | |
Kidney Transplantation, Bioengineering, and Regeneration |
|
xxv | |
|
|
|
Section I Epidemiology of Kidney Disease and Transplantation |
|
|
|
1 Epidemiology of End-Stage Renal Failure: The Burden of Kidney Diseases to Global Health |
|
|
|
|
|
|
1.1 The Global Burden of Noncommunicable Diseases |
|
|
5 | (1) |
|
1.2 Global Incidence and Prevalence of Chronic Kidney Disease and End-Stage Renal Disease |
|
|
6 | (3) |
|
|
9 | (4) |
|
|
9 | (4) |
|
2 Transplant Programs Worldwide and the Spanish Miracle |
|
|
|
|
|
|
|
|
|
|
13 | (2) |
|
2.2 The Spanish Model of Organ Donation and Transplantation |
|
|
15 | (1) |
|
2.3 Donor Coordination Network |
|
|
16 | (1) |
|
2.4 Specific Profile of the Donor Coordinator |
|
|
16 | (1) |
|
2.5 ONT as a Central Agency in Support of the System |
|
|
17 | (1) |
|
2.6 Quality Assurance Program in Deceased Donation |
|
|
17 | (1) |
|
2.7 Continuous Professional Training |
|
|
18 | (1) |
|
2.8 Close Cooperation With the Media |
|
|
18 | (1) |
|
2.9 Reimbursement of Donation and Procurement Activities |
|
|
18 | (1) |
|
2.10 Current Challenges in Organ Donation in Spain |
|
|
19 | (1) |
|
2.11 The 40 Donors per Million Population Plan |
|
|
20 | (1) |
|
2.12 Promoting the Identification of Possible Organ Donors Outside of the ICU and Considering Elective Nontherapeutic Intensive Care |
|
|
20 | (2) |
|
2.13 Fostering the Use of Organs From Expanded Criteria and Nonstandard Risk Donors |
|
|
22 | (1) |
|
2.14 Developing the Framework for the Practice of Donation After Circulatory Death |
|
|
23 | (1) |
|
2.15 Promoting Living Kidney Donation While Ensuring Comprehensive Donor Protection and Care |
|
|
24 | (1) |
|
|
25 | (6) |
|
|
25 | (6) |
|
Section II Donor Selection and Allocation |
|
|
|
3 The Deceased Kidney Donor |
|
|
|
|
|
|
31 | (1) |
|
|
32 | (1) |
|
3.3 Expanding the Donor Pool |
|
|
32 | (5) |
|
|
37 | (4) |
|
|
37 | (4) |
|
|
|
|
|
|
|
|
|
41 | (1) |
|
|
42 | (1) |
|
|
43 | (4) |
|
4.4 Outcome and Complications of the Surgery for the Donor |
|
|
47 | (1) |
|
4.5 Life Expectancy of the Donor |
|
|
47 | (4) |
|
|
48 | (3) |
|
5 Criteria for Kidney Allocation in the United States |
|
|
|
|
5.1 Introduction: History of Kidney Allocation |
|
|
51 | (1) |
|
5.2 Methods of Early Organ Sharing |
|
|
52 | (1) |
|
5.3 Evolution of National Organ Allocation Systems |
|
|
52 | (5) |
|
|
57 | (2) |
|
|
57 | (2) |
|
6 Strategies to Increase the Donor Pool |
|
|
|
|
|
|
59 | (1) |
|
|
60 | (2) |
|
|
62 | (5) |
|
|
67 | (1) |
|
6.5 Donor and Recipient Education |
|
|
68 | (2) |
|
6.6 Unrelated Donors and Solicitation |
|
|
70 | (1) |
|
|
70 | (3) |
|
6.8 Immunological Barriers |
|
|
73 | (1) |
|
6.9 Kidney Paired Donation |
|
|
74 | (3) |
|
|
77 | (10) |
|
|
77 | (10) |
|
Section III Kidney Preservation and Transplant Procedures |
|
|
|
|
|
|
|
|
|
7.1 Principles of Kidney Preservation |
|
|
87 | (1) |
|
|
88 | (1) |
|
7.3 Machine Perfusion Preservation |
|
|
89 | (7) |
|
|
96 | (5) |
|
|
97 | (4) |
|
8 Ex-vivo Normothermic Perfusion in Renal Transplantation |
|
|
|
|
|
|
101 | (1) |
|
8.2 The Origin of Normothermic Perfusion |
|
|
101 | (1) |
|
|
102 | (1) |
|
|
102 | (2) |
|
8.5 End Ex-vivo Normothermic Perfusion |
|
|
104 | (1) |
|
8.6 Intermediate Ex-vivo Normothermic Perfusion |
|
|
104 | (1) |
|
8.7 Kidney Manipulation/Conditioning |
|
|
105 | (1) |
|
|
106 | (1) |
|
8.9 Viability/Quality Assessment |
|
|
106 | (1) |
|
8.10 Summary & Conclusion |
|
|
107 | (4) |
|
|
107 | (4) |
|
9 Kidney Transplant Recipient Surgery |
|
|
|
|
|
|
|
|
|
111 | (1) |
|
9.2 Preparation of the Renal Graft (Synonymous to Bench Procedure or Benching) |
|
|
112 | (3) |
|
9.3 Standard Surgical Technique of Kidney Transplantation |
|
|
115 | (8) |
|
9.4 Surgical Considerations in Pediatric Recipients and Donors |
|
|
123 | (1) |
|
9.5 Orthotopic Kidney Transplantation |
|
|
124 | (1) |
|
|
124 | (3) |
|
|
125 | (2) |
|
10 Robotic-Assisted Kidney Transplantation |
|
|
|
|
|
|
|
|
|
127 | (1) |
|
10.2 University of Illinois' Experience |
|
|
127 | (3) |
|
|
130 | (1) |
|
|
131 | (1) |
|
|
132 | (3) |
|
|
132 | (3) |
|
11 Orthotopic Kidney Transplantation |
|
|
|
|
|
135 | (1) |
|
|
135 | (1) |
|
|
135 | (4) |
|
|
139 | (2) |
|
|
140 | (1) |
|
12 Kidney Transplantation Combined With Other Organs |
|
|
|
|
|
|
|
|
|
141 | (1) |
|
12.2 Kidney Combined With Pancreas Transplantation |
|
|
142 | (4) |
|
12.3 Kidney Combined With Liver Transplantation |
|
|
146 | (4) |
|
12.4 Kidney Combined With Heart Transplantation |
|
|
150 | (1) |
|
12.5 Protection of Kidney by Other Organs |
|
|
151 | (8) |
|
|
152 | (1) |
|
|
152 | (7) |
|
13 Pediatric Renal Transplantation |
|
|
|
|
|
|
|
159 | (1) |
|
|
160 | (1) |
|
13.2 Surgical Aspect of Pediatric Renal Transplantation |
|
|
161 | (1) |
|
|
162 | (2) |
|
13.4 Transplant Immunosuppression |
|
|
164 | (4) |
|
13.5 Metabolic Complications After Transplantation |
|
|
168 | (1) |
|
|
169 | (2) |
|
|
171 | (1) |
|
13.8 Cancer After Kidney Transplantation |
|
|
171 | (1) |
|
|
172 | (1) |
|
|
173 | (14) |
|
|
174 | (13) |
|
Section IV Kidney Recipient: Before and Peritransplant |
|
|
|
14 Indications for Renal Transplantation: Evaluation of Transplant Candidates |
|
|
|
|
|
|
187 | (1) |
|
14.2 Indications and Contraindications |
|
|
188 | (1) |
|
14.3 Pretransplant Evaluation for Transplant Candidates |
|
|
189 | (5) |
|
14.4 Pretransplant Renal and Systemic Diseases |
|
|
194 | (1) |
|
14.5 Reevaluation After Waitlisting |
|
|
195 | (4) |
|
|
195 | (4) |
|
15 Early Postoperative ICU Care of the Kidney Transplant Recipient |
|
|
|
|
Diego Castanares-Zapatero |
|
|
|
|
|
|
|
199 | (1) |
|
|
199 | (3) |
|
15.3 Central Venous Pressure Monitoring |
|
|
202 | (1) |
|
15.4 Dopamine and Other Medications |
|
|
203 | (2) |
|
15.5 Abdominal Compartment Syndrome and Renal Allograft Compartment Syndrome |
|
|
205 | (1) |
|
15.6 Other Considerations |
|
|
206 | (1) |
|
|
206 | (5) |
|
|
206 | (5) |
|
16 Approaches to Minimize Delayed Graft Function in Renal Transplantation |
|
|
|
|
|
|
211 | (1) |
|
|
211 | (1) |
|
|
212 | (1) |
|
|
212 | (1) |
|
|
213 | (1) |
|
16.5 New Biomarkers and Predictive Models |
|
|
213 | (1) |
|
|
214 | (1) |
|
16.7 Interventions and Approaches to the Patient With DGF |
|
|
215 | (1) |
|
|
216 | (7) |
|
|
217 | (6) |
|
Section V Transplantation Immunology and Immunomodulation |
|
|
|
17 Histocompatibility Testing in the Transplant Setting |
|
|
|
|
|
223 | (1) |
|
|
223 | (2) |
|
17.3 Histocompatibility Testing |
|
|
225 | (8) |
|
|
233 | (2) |
|
|
233 | (2) |
|
18 The Immune Response to the Allograft |
|
|
|
|
|
|
235 | (1) |
|
18.2 Ischemia Reperfusion |
|
|
235 | (1) |
|
18.3 T Cells and Mechanisms of Allorecognition |
|
|
236 | (2) |
|
|
238 | (1) |
|
18.5 The Immune Response Following Immunosuppression |
|
|
239 | (1) |
|
18.6 New Therapies for the Induction of Tolerance |
|
|
240 | (1) |
|
|
241 | (6) |
|
|
241 | (1) |
|
|
241 | (6) |
|
19 Induction Immunosuppression in Kidney Transplantation |
|
|
|
|
|
|
247 | (1) |
|
19.2 Induction Immunosuppression in the Prevention of Acute Rejection |
|
|
247 | (5) |
|
19.3 Induction Immunosuppression in Low-Comorbidity Regimens |
|
|
252 | (2) |
|
19.4 Induction in High-Risk Patients |
|
|
254 | (1) |
|
19.5 Induction in the Prevention of Delayed Graft Function |
|
|
255 | (4) |
|
|
255 | (4) |
|
20 Maintenance Immunosuppression in Kidney Transplantation |
|
|
|
|
|
|
|
259 | (1) |
|
20.2 Immunosuppressive Agents to Target the Alloimmune Response |
|
|
260 | (1) |
|
|
261 | (1) |
|
20.4 Calcineurin Inhibitors |
|
|
262 | (3) |
|
20.5 Antiproliferative Agents |
|
|
265 | (1) |
|
20.6 The Mammalian Target of Rapamycin (mTOR) Inhibitors |
|
|
266 | (4) |
|
20.7 Costimulation Blockers |
|
|
270 | (1) |
|
20.8 Generic Immunosuppressive Medications |
|
|
271 | (6) |
|
|
272 | (5) |
|
21 Novel Drugs in Kidney Transplantation |
|
|
|
|
|
|
277 | (1) |
|
21.2 Therapies Targeting Delayed Graft Function |
|
|
277 | (3) |
|
21.3 Therapies Targeting Cellular Immunity |
|
|
280 | (5) |
|
21.4 Therapies Targeting Humoral Immunity |
|
|
285 | (6) |
|
|
287 | (4) |
|
22 Hematopoietic Stem Cell Transplantation for Induction of Allograft Tolerance |
|
|
|
|
|
|
|
|
291 | (1) |
|
22.2 Basic Studies in Rodents |
|
|
291 | (3) |
|
22.3 Preclinical Studies in Nonhuman Primates |
|
|
294 | (1) |
|
|
295 | (1) |
|
|
296 | (1) |
|
22.6 Massachusetts General Hospital |
|
|
297 | (1) |
|
22.7 Northwestern University |
|
|
297 | (1) |
|
|
298 | (5) |
|
|
299 | (1) |
|
|
299 | (4) |
|
23 Regulatory T Cell Therapy in Transplantation |
|
|
|
|
|
|
303 | (1) |
|
23.2 Treg Biology and Therapeutic Implications |
|
|
304 | (2) |
|
23.3 Tregs as Pharmaceuticals for Transplantation |
|
|
306 | (4) |
|
23.4 Clinical Experience Using Tregs |
|
|
310 | (3) |
|
23.5 Conclusions and Future Directions |
|
|
313 | (6) |
|
|
314 | (5) |
|
24 Mesenchymal Stromal Cells to Improve Solid Organ Transplant Outcome: Lessons From the Initial Clinical Trials |
|
|
|
|
|
|
|
|
319 | (1) |
|
24.2 Mesenchymal Stromal Cells |
|
|
319 | (1) |
|
24.3 The Role of MSCs in Immune Modulation |
|
|
320 | (1) |
|
24.4 The Role of MSCs in Tissue Repair |
|
|
321 | (1) |
|
24.5 Experimental Studies With MSCs in Renal Transplantation |
|
|
322 | (1) |
|
24.6 Clinical Trials With MSCs After Renal Transplantation |
|
|
323 | (5) |
|
24.7 Conclusion and Future Directions |
|
|
328 | (5) |
|
|
328 | (5) |
|
25 Renal Transplantation Across HLA and ABO Barriers |
|
|
|
|
|
|
333 | (1) |
|
|
333 | (1) |
|
25.3 Advantages of Desensitization |
|
|
334 | (2) |
|
25.4 Desensitization Modalities |
|
|
336 | (9) |
|
25.5 Kidney-Paired Donation |
|
|
345 | (2) |
|
|
347 | (10) |
|
|
348 | (9) |
|
Section VI Graft Monitoring Tools |
|
|
|
26 Pathology of the Renal Allograft |
|
|
|
|
|
|
|
|
357 | (1) |
|
26.2 Biopsy and Specimens |
|
|
357 | (1) |
|
|
358 | (4) |
|
|
362 | (4) |
|
|
366 | (2) |
|
26.6 Posttransplant Lymphoproliferative Disorders (PTLD) |
|
|
368 | (1) |
|
|
369 | (4) |
|
|
371 | (2) |
|
27 Imaging-Based Monitoring of the Renal Graft |
|
|
|
|
|
|
373 | (1) |
|
27.2 Renal Transplant Anatomy |
|
|
373 | (1) |
|
|
373 | (3) |
|
27.4 Complications: Nonvascular and Vascular |
|
|
376 | (14) |
|
27.5 Other Imaging Modalities |
|
|
390 | (4) |
|
27.6 New Developments in Transplant Ultrasound |
|
|
394 | (5) |
|
|
399 | (4) |
|
|
399 | (4) |
|
28 Immune Monitoring in Kidney Transplantation |
|
|
|
|
|
|
|
403 | (1) |
|
28.2 Current Standards of Immune Monitoring |
|
|
403 | (3) |
|
|
406 | (1) |
|
28.4 Disadvantages of Current Standards |
|
|
406 | (1) |
|
28.5 Noninvasive Monitoring |
|
|
407 | (6) |
|
|
413 | (6) |
|
|
413 | (6) |
|
29 Renal Function Measurements |
|
|
|
|
|
419 | (1) |
|
29.2 Methods to Evaluate Renal Function |
|
|
419 | (1) |
|
29.3 Estimation of Glomerular Filtration Rate |
|
|
419 | (6) |
|
|
425 | (4) |
|
|
425 | (1) |
|
|
425 | (4) |
|
30 Pharmacokinetics and Genomics of Immunosuppressive Drugs |
|
|
|
|
|
429 | (1) |
|
|
430 | (2) |
|
|
432 | (2) |
|
|
434 | (1) |
|
|
435 | (1) |
|
|
436 | (1) |
|
|
437 | (1) |
|
|
438 | (1) |
|
|
439 | (6) |
|
|
440 | (5) |
|
31 Gene Expression Technology Applied to Kidney Transplantation |
|
|
|
|
|
|
445 | (1) |
|
31.2 Gene Expression Measure in Renal Transplantation |
|
|
445 | (1) |
|
31.3 Gene Expression Associated With Pre- or Peritransplantation Factors |
|
|
446 | (2) |
|
31.4 Gene Expression to Assess and Diagnose Acute Renal Rejection |
|
|
448 | (2) |
|
31.5 Microarray Analysis in Chronic Allograft Injury |
|
|
450 | (1) |
|
31.6 Immunosuppressive Drugs in Transplantation |
|
|
451 | (2) |
|
|
453 | (8) |
|
|
453 | (8) |
|
Section VII Early Posttransplant Immune Events |
|
|
|
32 Acute Cellular Rejection |
|
|
|
|
|
|
|
461 | (1) |
|
|
461 | (2) |
|
|
463 | (1) |
|
|
464 | (1) |
|
|
464 | (4) |
|
|
468 | (2) |
|
32.7 Impact and Prognosis of Acute Cellular Rejection |
|
|
470 | (5) |
|
|
470 | (5) |
|
33 Acute Antibody-Mediated Rejection |
|
|
|
|
|
|
475 | (1) |
|
33.2 Risk Factors, Prevalence, and Clinical Presentation |
|
|
475 | (1) |
|
|
476 | (1) |
|
|
477 | (14) |
|
|
485 | (6) |
|
Section VIII Early and Late I Complications |
|
|
|
34 Vascular Complications in Renal Transplantation |
|
|
|
|
|
|
|
|
491 | (1) |
|
34.2 Arterial Complications After Renal Transplantation |
|
|
491 | (5) |
|
34.3 Renal Vein Complications After Kidney Transplantation |
|
|
496 | (1) |
|
|
497 | (1) |
|
34.5 Vascular Complications at the Backtable |
|
|
498 | (5) |
|
|
500 | (3) |
|
35 Infections in Kidney Transplant Recipients |
|
|
|
|
|
|
35.1 Timeline of Infections |
|
|
503 | (1) |
|
35.2 Pretransplant Screening of the Kidney Donor and Recipient |
|
|
504 | (1) |
|
35.3 Donor-Derived Infections |
|
|
504 | (1) |
|
|
504 | (5) |
|
|
509 | (4) |
|
|
510 | (3) |
|
36 Metabolic Disorders Following Kidney Transplantation |
|
|
|
|
|
|
513 | (1) |
|
|
513 | (3) |
|
|
516 | (3) |
|
36.4 Uric Acid Metabolism |
|
|
519 | (6) |
|
|
520 | (5) |
|
37 Cancer After Kidney Transplantation |
|
|
|
|
|
|
|
|
525 | (1) |
|
|
525 | (2) |
|
37.3 Cancer in Kidney Transplant Recipients |
|
|
527 | (4) |
|
|
531 | (2) |
|
37.5 Focus on Posttransplantation Lymphoproliferative Disorders |
|
|
533 | (10) |
|
|
537 | (6) |
|
38 Cardiovascular Disease and Renal Transplantation |
|
|
|
|
|
|
|
|
|
|
543 | (1) |
|
38.2 Assessment and Management of Cardiovascular Disease Pretransplantation |
|
|
543 | (3) |
|
38.3 Assessment and Management of Cardiovascular Disease Posttransplantation |
|
|
546 | (6) |
|
|
552 | (5) |
|
|
552 | (5) |
|
Section IX Long-term Outcomes |
|
|
|
39 Graft and Patient Survival |
|
|
|
|
|
|
|
|
|
|
|
557 | (1) |
|
|
558 | (1) |
|
|
558 | (2) |
|
|
560 | (1) |
|
39.4 Subclinical Allograft Dysfunction and Protocol Biopsies |
|
|
561 | (5) |
|
39.5 Combined Endpoints as Surrogate Measures for Kidney Transplant Outcome |
|
|
566 | (2) |
|
|
568 | (5) |
|
|
568 | (5) |
|
40 Urological Complications of the Renal Graft |
|
|
|
|
|
|
573 | (1) |
|
40.2 Urological Complications Overview |
|
|
573 | (3) |
|
40.3 Early Onset Urological Complications of Renal Transplant |
|
|
576 | (3) |
|
40.4 Late Onset Urological Complications of Renal Transplantation |
|
|
579 | (5) |
|
|
584 | (5) |
|
|
584 | (5) |
|
41 Impact of De Novo Donor-specific Alloantibody in Primary Renal Allografts |
|
|
|
|
|
589 | (1) |
|
|
589 | (1) |
|
41.3 Progression of DSA and Alloimmune Injury |
|
|
590 | (1) |
|
41.4 Good Graft Function With dnDSA |
|
|
591 | (1) |
|
41.5 IgG DSA Screening in Posttransplant Patients |
|
|
591 | (1) |
|
|
592 | (1) |
|
41.7 Therapeutic Options for Treatment of dnDSA |
|
|
592 | (1) |
|
41.8 Therapeutic Goals for Treatment of dnDSA |
|
|
592 | (1) |
|
41.9 Future Research for dnDSA |
|
|
593 | (1) |
|
|
593 | (4) |
|
|
593 | (4) |
|
42 De Novo and Recurrence of Renal Disease |
|
|
|
|
|
|
42.1 Renal Disease Recurrence: Introduction |
|
|
597 | (1) |
|
42.2 Recurrence of Primary Disease |
|
|
597 | (2) |
|
42.3 Recurrence of Secondary Disease |
|
|
599 | (3) |
|
|
602 | (9) |
|
|
604 | (7) |
|
Section X Transplant Issues in Specific Patient Groups |
|
|
|
43 Kidney Transplantation in the Elderly |
|
|
|
|
|
611 | (1) |
|
|
611 | (2) |
|
43.2 New Kidney Allocation Policy in the United States |
|
|
613 | (5) |
|
43.3 Immunosuppression in the Elderly |
|
|
618 | (1) |
|
43.4 Graft Survival and Lifespan |
|
|
619 | (1) |
|
43.5 Death With a Functioning Graft |
|
|
620 | (1) |
|
43.6 Patient Survival and Longevity |
|
|
620 | (1) |
|
|
621 | (1) |
|
43.8 Wake Forest Experience |
|
|
621 | (6) |
|
|
627 | (6) |
|
|
627 | (6) |
|
44 Dual Kidney Transplantation |
|
|
|
|
|
|
|
633 | (1) |
|
44.2 The Use of Expanded Criteria Donors as a Strategy to Increase the Donor Pool |
|
|
633 | (1) |
|
44.3 Preimplantation Biopsy Evaluation as an Option to Optimize the Use of Kidneys From Expanded Criteria Donors |
|
|
634 | (3) |
|
44.4 Is There an Age Limit to Donate Kidneys Allocated According to Pretransplant Biopsy Score? |
|
|
637 | (1) |
|
44.5 Is There an Age Limit to Receive a Dual Kidney Transplant? |
|
|
637 | (1) |
|
44.6 Operative Technique and Immunosuppressive Therapy |
|
|
638 | (1) |
|
44.7 Complications of Dual Kidney Transplantation |
|
|
638 | (1) |
|
44.8 How to Further Improve the Location and Performance of Organs From Expanded Criteria Donors? |
|
|
639 | (1) |
|
|
640 | (3) |
|
|
640 | (1) |
|
|
640 | (3) |
|
45 Kidney Transplantation in the Diabetic Patient |
|
|
|
|
|
|
643 | (1) |
|
45.1 Epidemiology, Classification and Consequences of Diabetes Mellitus |
|
|
643 | (1) |
|
45.2 Diabetic Kidney Disease and Transplant Treatment Options |
|
|
644 | (9) |
|
|
649 | (4) |
|
46 Kidney Transplantation in the Hepatitis C Infected Recipient |
|
|
|
|
|
|
|
653 | (1) |
|
46.2 Epidemiology and Risk Factors of HCV Infection in Patients With Chronic Renal Disease |
|
|
654 | (1) |
|
46.3 Screening and Diagnosis of HCV Infection in Patients With ESRD |
|
|
654 | (1) |
|
46.4 Evaluation of the HCV-Related Liver Disease |
|
|
655 | (1) |
|
46.5 Natural History of HCV Infection in Patient With End-Stage Renal Disease |
|
|
656 | (1) |
|
46.6 Natural History of HCV Infection After KT |
|
|
656 | (2) |
|
46.7 Immunosuppression in HCV-Positive KT Recipients |
|
|
658 | (1) |
|
46.8 Current Perspectives of Treatment of HCV-Infected Patients on Hemodialysis and in KT Recipients With Antivirals |
|
|
659 | (6) |
|
|
660 | (5) |
|
47 Pregnancy After Kidney Transplantation |
|
|
|
Marialuisa Framarino-Dei-Malatesta |
|
|
47.1 Introduction: From the Past to the Present |
|
|
665 | (1) |
|
|
665 | (2) |
|
47.3 Effect of KT on Pregnancy |
|
|
667 | (4) |
|
47.4 Effect "of Pregnancy on the Graft |
|
|
671 | (1) |
|
|
672 | (1) |
|
|
672 | (1) |
|
47.7 Algorithm for Prenatal and Pregnancy Care in Transplanted Patients |
|
|
673 | (4) |
|
|
674 | (3) |
|
48 Nutrition of the Kidney Transplant Recipients |
|
|
|
|
|
|
677 | (1) |
|
48.2 Pretransplant Nutrition Assessment and Management |
|
|
677 | (2) |
|
48.3 Nutrition and the Live Kidney Donor |
|
|
679 | (1) |
|
48.4 Posttransplant Nutritional Management in Adults |
|
|
679 | (2) |
|
48.5 Nutrition Management After Pediatric Kidney Transplantation |
|
|
681 | (6) |
|
|
681 | (6) |
|
Section XI Ethics and Costs |
|
|
|
49 Kidney Transplantation in Developing Countries |
|
|
|
|
|
|
|
|
687 | (1) |
|
49.2 Global Perspective of Kidney Disease and Renal Replacement Therapy |
|
|
688 | (1) |
|
49.3 Kidney Transplantation in Developing Countries |
|
|
689 | (8) |
|
|
697 | (2) |
|
|
697 | (2) |
|
50 Health-Related Quality of Life Outcomes After Kidney Transplantation |
|
|
|
|
|
|
|
699 | (1) |
|
|
699 | (1) |
|
50.2 Tools to Measure HRQOL |
|
|
700 | (1) |
|
50.3 Kidney Transplantation Improves HRQOL |
|
|
701 | (2) |
|
50.4 Factors Influencing HRQOL After Kidney Transplant |
|
|
703 | (2) |
|
|
705 | (4) |
|
|
706 | (3) |
|
51 Costs of Kidney Transplantation |
|
|
|
|
|
|
|
709 | (1) |
|
51.2 Financing of End Stage Renal Care |
|
|
709 | (2) |
|
51.3 Clinical and Economic Benefits of Renal Transplantation |
|
|
711 | (1) |
|
51.4 Economic Implications of Donor Characteristics |
|
|
712 | (2) |
|
51.5 Patient Characteristics |
|
|
714 | (1) |
|
51.6 The Economic Implications of Novel Approaches to Increase Access to Organ Transplant |
|
|
715 | (1) |
|
51.7 Summary and Conclusions |
|
|
716 | (5) |
|
|
717 | (4) |
|
|
|
52 Kidney Transplantation: Have the Promises Been Kept and Needs Met |
|
|
|
|
|
|
|
721 | (1) |
|
52.2 Historical Background |
|
|
722 | (1) |
|
52.3 Promises and Needs Met |
|
|
723 | (3) |
|
52.4 Promises and Needs Remaining |
|
|
726 | (7) |
|
|
733 | (4) |
|
|
734 | (3) |
|
53 Innovations in Kidney Transplant Research |
|
|
|
|
|
|
|
737 | (1) |
|
53.1 Innate Lymphoid Cells |
|
|
738 | (2) |
|
|
740 | (5) |
|
|
745 | (12) |
|
|
749 | (8) |
|
II KIDNEY BIOENGINEERING AND REGENERATION |
|
|
|
|
|
54 Converging Organ Transplantation Towards Regenerative Medicine |
|
|
|
|
|
|
|
|
757 | (1) |
|
|
757 | (2) |
|
54.2 The Demand for Transplantable Organs |
|
|
759 | (1) |
|
54.3 Shortcomings of Organ Transplantation |
|
|
759 | (1) |
|
54.4 Challenges Associated With Antirejection Therapy |
|
|
760 | (1) |
|
54.5 Regenerative Medicine and Organ Bioengineering |
|
|
760 | (5) |
|
|
765 | (4) |
|
|
765 | (4) |
|
55 A Systems Engineering Approach to Restoring Kidney Structure and Function |
|
|
|
|
|
769 | (1) |
|
55.2 The Targets of Engineered Solutions to Kidney Failure |
|
|
770 | (5) |
|
55.3 Specific Engineering Challenges in Restoring Kidney Function |
|
|
775 | (6) |
|
|
781 | (6) |
|
|
782 | (5) |
|
Section II Kidney Development |
|
|
|
56 Kidney Development in the Mammal |
|
|
|
|
|
787 | (1) |
|
56.2 Formation of the Excretory System from the Intermediate Mesoderm |
|
|
787 | (2) |
|
56.3 Initiation of the Metanephros and Early Morphogenetic Events |
|
|
789 | (1) |
|
56.4 A Progenitor for the Collecting Ducts Within the Branching Ureteric Epithelium |
|
|
789 | (3) |
|
56.5 The Nephron Progenitor Population Balancing Self-Renewal With Nephron Induction |
|
|
792 | (1) |
|
56.6 A Stromal Progenitor Population Gives Rise to Perivascular and Mesangial Cells and Regulates Kidney Patterning |
|
|
793 | (1) |
|
56.7 Vascular Progenitors and Their Role in Formation of the Renal Vasculature |
|
|
793 | (1) |
|
56.8 Nephron Induction, Segmentation, and Functionalization |
|
|
794 | (1) |
|
56.9 Cessation of Nephrogenesis |
|
|
795 | (1) |
|
|
795 | (6) |
|
|
796 | (5) |
|
57 Renal Branching Morphogenesis |
|
|
|
|
|
|
801 | (1) |
|
|
801 | (1) |
|
57.2 Overview of Renal Branching Morphogenesis |
|
|
802 | (1) |
|
57.3 Specification and Patterning of the Nephric Duct |
|
|
803 | (2) |
|
57.4 Specification of the Ureteric Bud Site |
|
|
805 | (2) |
|
57.5 Branching of the Ureteric Bud and Its Derivatives |
|
|
807 | (3) |
|
57.6 Cessation of Renal Branching Morphogenesis |
|
|
810 | (1) |
|
57.7 Conclusions and Implications for Tissue Regeneration |
|
|
811 | (6) |
|
|
811 | (1) |
|
|
811 | (6) |
|
Section III Bioengineering |
|
|
|
58 Principles of Stem Cell Biology Applied to the Kidney |
|
|
|
|
|
58.1 The Fundamental Cellular Principles of Living Systems |
|
|
817 | (1) |
|
58.2 Cellular Diversity Through Differentiation |
|
|
818 | (1) |
|
58.3 Revelations of Embryonic Cell Potency and Differentiation From Developmental Biology |
|
|
819 | (1) |
|
58.4 The Discovery of Adult Stem Cells, Their Properties, and Residence in Homes Called Niches |
|
|
820 | (2) |
|
58.5 The Stem Cell Paradigm, Genomic Equivalence, and Plasticity of Cellular States |
|
|
822 | (1) |
|
58.6 Kidney Stem Cells During Development |
|
|
822 | (2) |
|
58.7 The Adult Kidney: Conflicting Evidence About Sternness, Plasticity, and Dedifferentiation |
|
|
824 | (1) |
|
58.8 Conclusions and Future Prospects |
|
|
825 | (4) |
|
|
825 | (1) |
|
|
825 | (4) |
|
59 Extracellular Matrix Biology Applied to the Kidney |
|
|
|
|
|
829 | (1) |
|
59.2 Extracellular Matrix |
|
|
829 | (2) |
|
59.3 Extracellular Matrix in Kidney Health and Disease |
|
|
831 | (5) |
|
59.4 Matrix-Targeted Therapy |
|
|
836 | (2) |
|
|
838 | (5) |
|
|
838 | (5) |
|
60 Interplay Between Growth Factor Receptors, Small GTPases, and Mechanical Stress in the Maintenance of Kidney Glomerular Homeostasis |
|
|
|
|
|
|
|
|
843 | (1) |
|
|
843 | (2) |
|
60.2 Growth Factors and Glomerulosclerosis |
|
|
845 | (4) |
|
60.3 Small Rho GTPase and Glomerulosclerosis |
|
|
849 | (3) |
|
60.4 Cytoskeletal Proteins |
|
|
852 | (1) |
|
|
853 | (1) |
|
|
854 | (7) |
|
|
855 | (1) |
|
|
855 | (6) |
|
61 Bioengineering Approach to Immunomodulation |
|
|
|
|
|
|
861 | (1) |
|
61.2 An Alternative Approach |
|
|
862 | (7) |
|
|
869 | (4) |
|
|
870 | (3) |
|
62 Principles of Organ Bioengineering |
|
|
|
|
|
|
|
|
873 | (1) |
|
|
873 | (1) |
|
|
874 | (1) |
|
|
874 | (1) |
|
|
874 | (1) |
|
|
875 | (1) |
|
|
875 | (1) |
|
|
875 | (2) |
|
|
876 | (1) |
|
63 Recellularization of Kidney Scaffold With Stem Cells |
|
|
|
|
|
|
|
877 | (1) |
|
63.2 Stem Cells for Kidney Tissue Engineering |
|
|
878 | (2) |
|
63.3 Cell Seeding in the Rat Kidney |
|
|
880 | (2) |
|
63.4 Cell Seeding in the Kidney of Large Animals |
|
|
882 | (1) |
|
63.5 Cell Seeding in the Human Kidney |
|
|
883 | (1) |
|
|
883 | (6) |
|
|
884 | (1) |
|
|
884 | (5) |
|
Section IV Bioreactors and Biomaterials |
|
|
|
64 Bioreactors for Cell Culture Systems and Organ Bioengineering |
|
|
|
|
|
|
889 | (1) |
|
64.2 Bioreactors Design: General Parameters and Specific Features |
|
|
890 | (1) |
|
64.3 Bioreactor Systems for Tissue Engineering |
|
|
891 | (1) |
|
64.4 Impact of Biomimetic and Microenvironmental Stimuli on Tissue Development |
|
|
892 | (1) |
|
|
892 | (3) |
|
64.6 Bioreactors and Whole-Organ Bioengineering |
|
|
895 | (2) |
|
64.7 Conclusions and Remarks |
|
|
897 | (4) |
|
|
897 | (1) |
|
|
897 | (4) |
|
65 Synthetic Biomaterial for Regenerative Medicine Applications |
|
|
|
|
|
|
|
|
|
|
|
901 | (3) |
|
65.2 Relevant Biomaterial Properties in TE Field |
|
|
904 | (2) |
|
65.3 Nondegradable Polymers |
|
|
906 | (1) |
|
|
907 | (2) |
|
|
909 | (3) |
|
|
912 | (3) |
|
65.7 Conclusions and Future Directions |
|
|
915 | (8) |
|
|
915 | (1) |
|
|
915 | (8) |
|
66 Immune Responses to Biomaterials Used in Renal Engineering |
|
|
|
|
|
923 | (1) |
|
66.2 The Immunological Basis of Biocompatibility |
|
|
924 | (3) |
|
66.3 Immunological Aspects of Biocompatibility Phenomena in Renal Technologies |
|
|
927 | (4) |
|
|
931 | (6) |
|
|
931 | (6) |
|
|
|
67 Regeneration of Kidney From Human Reprogrammed Stem Cells |
|
|
|
|
|
|
937 | (1) |
|
67.2 The Origin of the Cellular Components of the Kidney |
|
|
938 | (1) |
|
67.3 Possible Options for Regenerating Kidney Tissues |
|
|
939 | (2) |
|
67.4 Direct Differentiation of Pluripotent Stem Cells to Kidney Progenitor States |
|
|
941 | (4) |
|
67.5 Challenges to the Generation of Kidney From Pluripotent Stem Cells |
|
|
945 | (2) |
|
67.6 Possible Applications of Stem-Cell Derived Renal Cells |
|
|
947 | (3) |
|
|
950 | (7) |
|
|
951 | (1) |
|
|
951 | (6) |
|
68 Bioprinting Complex 3D Tissue and Organs |
|
|
|
|
|
|
|
957 | (1) |
|
|
958 | (1) |
|
68.3 Technological Strategies |
|
|
959 | (3) |
|
|
962 | (2) |
|
|
964 | (2) |
|
68.6 Progress and Challenges for Kidney Bioprinting |
|
|
966 | (1) |
|
|
967 | (6) |
|
|
967 | (6) |
|
69 Principles of Kidney Regeneration |
|
|
|
|
|
|
|
|
|
973 | (1) |
|
69.2 Kidney Regeneration From Evolution to Mammalian Renal Development |
|
|
973 | (3) |
|
69.3 Clinical and Experimental Evidence of Kidney Regeneration |
|
|
976 | (2) |
|
69.4 Renal Progenitor Cells in Adult Kidney and Their Role in Glomerular and Tubular Regeneration |
|
|
978 | (6) |
|
|
984 | (5) |
|
|
985 | (4) |
|
70 Markers of Repair and Regeneration in the Marginal Kidney |
|
|
|
|
|
|
989 | (1) |
|
70.2 Defining the Marginal Kidney |
|
|
989 | (1) |
|
|
990 | (2) |
|
70.4 The Renal Repair/Regeneration Process |
|
|
992 | (1) |
|
70.5 Evaluating Posttransplantation Renal Function |
|
|
993 | (1) |
|
70.6 Molecular Profiling in the Field of Kidney Transplantation |
|
|
994 | (1) |
|
|
994 | (3) |
|
|
995 | (2) |
|
71 Nephron Repair in Mammals and Fish |
|
|
|
|
|
|
|
997 | (1) |
|
71.2 Proximal Tubule Repair in Mammals |
|
|
997 | (2) |
|
71.3 Proximal Tubule Repair in Fish |
|
|
999 | (1) |
|
71.4 Neonephrogenesis in Fish |
|
|
1000 | (2) |
|
|
1002 | (3) |
|
|
1002 | (3) |
|
72 Imaging of Glomerular Regeneration |
|
|
|
|
|
|
72.1 High-Power Multiphoton Microscopy Imaging: A Technical Breakthrough for Glomerular Studies |
|
|
1005 | (1) |
|
72.2 Intravital Imaging of the Glomerulus With Conventional Huorescent Probes |
|
|
1006 | (2) |
|
72.3 The Combination of Two State-of-the-Art Technologies for Glomerular Studies: Intravital Imaging and Mouse Genetics |
|
|
1008 | (1) |
|
72.4 Serial Multiphoton Microscopy Imaging of the Remodeling Glomerulus |
|
|
1009 | (1) |
|
|
1009 | (4) |
|
|
1009 | (1) |
|
|
1009 | (4) |
|
73 Reversibility of Renal Fibrosis |
|
|
|
Christos E. Chadjichristos |
|
|
|
|
|
|
|
1013 | (1) |
|
73.2 Current Mediators of Renal Fibrosis |
|
|
1013 | (3) |
|
73.3 New Mediators of Renal Fibrosis |
|
|
1016 | (3) |
|
|
1019 | (6) |
|
|
1019 | (6) |
|
74 Pharmacological Induction of Kidney Regeneration |
|
|
|
|
|
|
|
1025 | (1) |
|
74.2 Kidney Regeneration in Experimental AKI |
|
|
1025 | (4) |
|
74.3 Kidney Regeneration in Experimental CKD |
|
|
1029 | (3) |
|
74.4 Kidney Regeneration in Humans |
|
|
1032 | (1) |
|
|
1033 | (6) |
|
|
1034 | (1) |
|
|
1034 | (5) |
|
75 Developmental Approaches to Kidney Regeneration |
|
|
|
|
|
|
|
|
1039 | (1) |
|
75.2 Transplantation of Embryonic Kidney Tissues |
|
|
1039 | (4) |
|
75.3 Engineering Kidney Tissue Using Embryonic Kidney Cells |
|
|
1043 | (3) |
|
75.4 Blastocyst Complementation |
|
|
1046 | (1) |
|
|
1047 | (6) |
|
|
1047 | (1) |
|
|
1048 | (5) |
|
Section VI Adult Cells for Regeneration |
|
|
|
|
|
|
|
|
|
1053 | (1) |
|
76.2 Sources of Nephron Progenitor Cells |
|
|
1054 | (3) |
|
76.3 Characterization of Nephron Progenitor Cells Isolated From Kidneys |
|
|
1057 | (1) |
|
76.4 The Potential of Nephron Progenitors in Regenerative Medicine |
|
|
1058 | (9) |
|
|
1062 | (5) |
|
77 Urine Progenitor Cells for Potential Application in Renal Tissue Repair |
|
|
|
|
|
|
|
|
|
1067 | (1) |
|
77.2 Stem Cell Properties of USCs |
|
|
1068 | (3) |
|
77.3 Generation of iPSCs From USCs (U-iPSCs) |
|
|
1071 | (1) |
|
|
1071 | (1) |
|
|
1072 | (1) |
|
|
1072 | (3) |
|
|
1072 | (1) |
|
|
1072 | (3) |
|
78 Endothelial Progenitor Cells in Kidney Disease |
|
|
|
|
|
1075 | (1) |
|
78.2 EPC Ontogeny and Presumed Role |
|
|
1075 | (2) |
|
|
1077 | (1) |
|
|
1077 | (1) |
|
78.5 EPC Secretome and Angiocrine Signaling |
|
|
1078 | (1) |
|
78.6 EPC in Sepsis: Use of Scaffolds to Adoptively Transfer EPC |
|
|
1079 | (1) |
|
78.7 EPC-Induced Macrophage Polarization |
|
|
1079 | (1) |
|
78.8 Use of EPC Extract to Combat CKD and Fibrogenesis |
|
|
1079 | (1) |
|
78.9 EPC Rejuvenation: NAD, SIRTI, Ebselen, mTOR, AMPK, Inhibitors of GSK-3ß |
|
|
1079 | (6) |
|
|
1080 | (1) |
|
|
1080 | (5) |
|
Section VII Cell Therapy For Renal Tissue Repair |
|
|
|
79 Mesenchymal Stromal Cells for Acute Renal Injury |
|
|
|
|
Serge Cedrick Mbiandjeu Toya |
|
|
|
|
1085 | (1) |
|
79.2 Mesenchymal Stem Cells |
|
|
1085 | (7) |
|
79.3 Conclusions and Perspectives |
|
|
1092 | (5) |
|
|
1093 | (4) |
|
80 Amniotic Fluid Cells: Kidney Injury and Regeneration |
|
|
|
|
|
|
|
1097 | (1) |
|
|
1097 | (1) |
|
80.3 Amniotic Fluid Cells: Selection, Characterization and Expansion |
|
|
1098 | (3) |
|
80.4 Amniotic Fluid Therapeutic Potential in Renal Injury |
|
|
1101 | (2) |
|
80.5 Kidney Regeneration and Bioengineering |
|
|
1103 | (1) |
|
|
1104 | (5) |
|
|
1104 | (5) |
|
81 Renal Cells From Spermatogonial Germline Stem Cells for Protection Against Kidney Injury |
|
|
|
|
|
|
|
|
|
1109 | (1) |
|
81.2 Spermatogonial Stem Cells |
|
|
1110 | (1) |
|
81.3 Germline Cell-Derived Pluripotent Stem Cells |
|
|
1110 | (4) |
|
|
1114 | (5) |
|
|
1114 | (1) |
|
|
1114 | (5) |
|
Section VIII Future Perspective |
|
|
|
82 Kidney-on-a-Chip: Technologies for Studying Pharmacological and Therapeutic Approaches to Kidney Repair |
|
|
|
|
|
|
|
1119 | (1) |
|
82.2 In Search for Translational Cell Models |
|
|
1120 | (3) |
|
82.3 Engineered Renal Models: From 1D to 3D |
|
|
1123 | (7) |
|
82.4 Future Prospects in Regenerative Nephropharmacology |
|
|
1130 | (5) |
|
|
1130 | (5) |
|
83 Renal Replacement Devices |
|
|
|
|
|
83.1 Overview of Renal Replacement |
|
|
1135 | (1) |
|
83.2 Membranes for Small-Solute Clearance |
|
|
1136 | (5) |
|
83.3 Endothelialized Membranes and Renal Epithelial Cell (REC) Therapy |
|
|
1141 | (4) |
|
83.4 Biomimetic Immunomodulatory Devices |
|
|
1145 | (1) |
|
|
1146 | (5) |
|
|
1147 | (4) |
|
84 Xenotransplantation and Kidney Regenerative Technology |
|
|
|
|
|
|
|
|
1151 | (1) |
|
84.2 Regeneration of the Kidney |
|
|
1151 | (1) |
|
84.3 Cell-Based Therapies |
|
|
1151 | (2) |
|
84.4 De Novo Organ Generation |
|
|
1153 | (1) |
|
|
1154 | (4) |
|
|
1158 | (5) |
|
|
1158 | (5) |
|
85 Embryonic Organoid Transplantation |
|
|
|
|
|
|
1163 | (1) |
|
85.2 Embryonic Kidney Transplantation for Kidney Regeneration |
|
|
1163 | (1) |
|
85.3 De Novo Kidney Regeneration Using the Organogenic Niche Method |
|
|
1164 | (1) |
|
|
1165 | (2) |
|
|
1165 | (2) |
|
86 Lineage Reprogramming Toward Kidney Regeneration |
|
|
|
|
|
|
Juan Carlos Izpisua Belmonte |
|
|
86.1 The Waddington Landscape: "Topping" Pluripotency |
|
|
1167 | (1) |
|
86.2 Reprogramming: Reverting Development |
|
|
1167 | (1) |
|
86.3 In vitro Lineage Specification: Choosing the Wanted Route |
|
|
1168 | (2) |
|
86.4 Representing Lineage Reprogramming From a Mathematical Point of View |
|
|
1170 | (1) |
|
86.5 How to Quantify Cellular Status During Lineage Reprogramming |
|
|
1170 | (1) |
|
86.6 Mathematical Approaches to Quantify Lineage Specification |
|
|
1171 | (2) |
|
|
1173 | (4) |
|
|
1173 | (1) |
|
|
1173 | (4) |
|
87 Regenerating Kidney Structure and Function: An Industry Perspective |
|
|
|
|
|
|
|
1177 | (1) |
|
87.2 Biomaterials: An Industry Perspective |
|
|
1177 | (1) |
|
87.3 Decell/Recell---the Ultimate Biomaterial Platform? |
|
|
1178 | (1) |
|
87.4 Selection of Biomaterials for Tissue Engineering: Kidney as an Illustrative Example |
|
|
1179 | (2) |
|
87.5 Biomaterial Candidates for Renal Tissue Engineering |
|
|
1181 | (2) |
|
87.6 Cells for Renal Tissue Engineering |
|
|
1183 | (1) |
|
|
1184 | (5) |
|
|
1186 | (3) |
Index |
|
1189 | |